Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2012 / Article

Research Article | Open Access

Volume 2012 |Article ID 967182 | https://doi.org/10.1155/2012/967182

Chang-Ching Lin, Hsien-Yuan Fan, Chien-Wen Kuo, Li-Heng Pao, "Evaluation of Chinese-Herbal-Medicine-Induced Herb-Drug Interactions: Focusing on Organic Anion Transporter 1", Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 967182, 12 pages, 2012. https://doi.org/10.1155/2012/967182

Evaluation of Chinese-Herbal-Medicine-Induced Herb-Drug Interactions: Focusing on Organic Anion Transporter 1

Academic Editor: Ke Liu
Received02 Feb 2012
Revised26 Jul 2012
Accepted30 Jul 2012
Published04 Sep 2012

Abstract

The consumption of Chinese herbal medicines (CHMs) is increasing exponentially. Many patients utilize CHMs concomitantly with prescription drugs in great frequency. Herb-drug interaction has hence become an important focus of study. Transporter-mediated herb-drug interactions have the potential to seriously influence drug efficacy and toxicity. Since organic anion transporter 1 (OAT1) is crucial in renal active secretion and drug-drug interactions, the possibility of modulation of OAT1-mediated drug transport should be seriously concerned. Sixty-three clinically used CHMs were evaluated in the study. An hOAT1-overexpressing cell line was used for the in vitro CHMs screening, and the effective candidates were administered to Wistar rats to access renal hemodynamics. The regulation of OAT1 mRNA expression was also examined for further evidence of CHMs affecting OAT1-mediated transport. Among all the 63 CHMs, formulae Gui Zhi Fu Ling Wan (GZ) and Chia Wei Hsiao Yao San (CW) exhibited significant inhibitions on hOAT1-mediated [3H]-PAH uptake in vitro and PAH clearance and net secretion in vivo. Moreover, GZ showed concentration-dependent manners both in vitro and in vivo, and the decrease of rOAT1 mRNA expression indicated that GZ not only inhibited function of OAT1 but also suppressed expression of OAT1.

1. Introduction

Traditional herbal medicines (THM) have been widely used as complementary alternative medicines (CAM) in the past few decades and the use of THM is continuously growing as one of the most popular CAM all over the world [15].

Among THM, Chinese herbal medicine (CHM) is a well defined and established therapeutic system. The therapeutic concepts of CHM are the use of herbal formulations to balance Yin and Yang, Qi and blood [6]. The approaches of CHM formulations are to combine different herbal compounds to increase or promote therapeutic effectiveness, minimize toxicity and side effects, accommodate the promotion of harmony, and optimize the therapeutic effect of each component [7]. CHM formulations are broadly used in global populations. For example, they are considered to be dietary supplements in the USA and natural health products in Canada and Australia. In Asia, they are used as prescriptive drugs in China, Japan, and Taiwan, where CHM is extensively prescribed for treating various kinds of diseases [3, 711].

Since the use of CHM is widespread all over the world, the possibility of herb-drug interactions (potential risks while CHM are taken concomitantly with drugs by patients) should be seriously heeded. Modulation of drug transporters by CHM is a proper example to elucidate herb-drug interactions that are mentioned above. Drug transporters are transmembrane proteins that deliver various endogenous and exogenous compounds across cell membranes. As efflux transporter like P-glycoprotein (P-gp) located on intestinal apical membrane is enhanced by CHM, drugs can be highly pumped out by P-gp, which leads to poor bioavailability of drugs [12, 13]. In fact, modulation of transporter-mediated drugs transport is much more complex; it may affect not only absorption of drugs, but also distribution, metabolism, and elimination [1417]. Once CHMs modulate transporters, they may influence pharmacokinetic of the concomitantly used drugs and further cause adverse effects.

Active secretion that occurs in proximal tubule of kidney is one of the major pathways of drug elimination. In transporters-mediated active secretion, the organic anion transporter (OAT) system is considered to play an important role because it excretes many phase II metabolites in addition to unconjugated anionic compounds against the concentration gradient. Thus the OAT system eliminates a large number of anionic xenobiotics, including a variety of drugs [1820].

OAT1 is the first cloned member of the OAT family [2123]. The mRNA expression of OAT1 is predominant in human and rat kidneys whereas it appears weakly in other organs [22, 24]. In kidney, OAT1 is localized at the basolateral membrane of proximal tubular cells [20, 25]. At first, the function of OAT1 was identified as p-aminohippuric acid (PAH)/dicarboxylate exchanger: OAT1 transports outward directly of dicarboxylate (physiologically, α-ketoglutarate) moving down its electrochemical gradient in the exchange for the uptake of PAH against its electrochemical gradient [2123, 26, 27].

OAT1 is multispecific in substrates, from endogenous substances to environmental toxins and drugs. Drugs that are transported by OAT1 include nonsteroidal anti-inflammatory drugs (NSAIDs), antiviral drugs, antibiotics, diuretics, antineoplasmics, antiepileptics, and antihypertensive agents [20, 2830]. Thus, inhibition of OAT1 may probably diminish renal excretion and increase body accumulation of these drugs, which may cause adverse effects. In Japan, it has been reported that severe bone marrow suppression occurred in patients who were coadministered methotrexate (MTX) and NSAIDs. Inhibition of OAT1-mediated MTX renal excretion by NSAIDs is also considered to play a role in the accumulation and adverse effects of MTX [31, 32]. In contrast to the adverse effects, several studies have reported that OAT1-mediated cellular accumulation of antiviral drugs is the reason of nephrotoxicity; hence, inhibition of OAT1 by NSAIDs or probenecid may, in some cases, reduce nephrotoxicity [15, 3336]. Besides, OAT1 also transports uremic toxins derived from dietary protein such as indoxyl sulfate, which plays an important role in the progression of renal damage. Therefore, OAT1 is important not only in the transport of drugs, but also in the progression of renal diseases.

Since OAT1 is crucial in renal active secretion and drug-drug interactions, the possibility of modulation of OAT1-mediated drug transport should be seriously concerned. The gradual increase of popularity of CHM arises more caution on drug safety. Once CHM significantly influences OAT1-mediated renal active secretion, especially while CHMs are coadministered with nonherbal drugs, herb-drug interactions may cause severe adverse effects.

With different ethnicity and culture, Asians are more prone to be encountered with Chinese herbal medicines. This study focused on the herb-drug interaction with the frequently used CHMs in Taiwan, China, and Japan, since CHMs are used in a great amount for disease treatment and supplementary in the daily diet. The purpose of this study is to evaluate the modulation effects of clinical frequently used CHM on OAT1-mediated transport. First, an hOAT1-overexpressing cell line was used to screen CHM, and then the effective candidates were reaffirmed to see whether they exhibited the same pattern in vivo. Finally, this study examined how these CHMs affect OAT1-mediated transport; by functional modulation, expressional regulation, or both.

2. Materials and Methods

2.1. Cell Culture

Control and stably hOAT1 expressing Madin-Darby canine kidney type II (MDCK/hOAT1) cells were kindly provided from Dr. Pritchard’s laboratory (National Institute of Environmental Health Sciences, USA). Control MDCK II cells were grown in Eagle’s Minimum Essential Medium (EMEM, Sigma-Aldrich, USA) supplemented with 1 mM sodium pyruvate and 10% fetal bovine serum (HyClone, USA); MDCK/hOAT1 cells were grown in the same EMEM medium with an extra 200 μg/mL Geneticin (Invitrogen, USA). While in culture, both cells were grown and maintained in a humidified atmosphere consisting of 5% CO2 at 37°C. Cells were split 1/10 every 4 to 5 days.

2.2. Chinese Herbal Medicine Formulae-Plant Materials: Sources, Sampling, Identification, Exaction Acquisition, and Physiochemical Analysis

All CHM formulae were purchased from Sun Ten GMP pharmaceutical company. Each plant of the CHM formulae was collected from different regions in China. Each plant was preserved as the voucher herbarium specimen and deposited at the Brion Research Institute (BRI, Taipei, Taiwan). The authentication of the plants was identified using microscopic and high-performance liquid chromatography (HPLC). All plant parts were classified according to the Pharmacopoeia of the People’s Republic of China [37].

Raw herbs were extracted by decoction using hot distilled water and concentrated using instant spray drying and low-temperature vacuuming. Validations of thin layer chromatography and high-performance liquid chromatography were performed as quality control for CHM single herbs and CHM formulae, respectively.

2.3. Extraction of Chinese Herbal Medicine Formulae for In Vitro Study

Clinical frequently used CHM formulae and single herbs were selected as candidates for the in vitro screening experiments [38]. CHM formulae were all purchased from a GMP pharmaceutical company (Sun Ten Pharmaceutical Co., LTD, Taiwan). All of the CHM formulae are available market products that are frequently prescribed in hospitals in Taiwan. Extraction of CHM formulae was prepared in a way to simulate the physiological condition when a CHM formula was ingested by oral administration in living organisms; CHM formulae are first exposed in extremely acidic conditions in the stomach and then are flowed into neutral conditions in the duodenum. An appropriate amount of CHM formulae was weighted and prepared at 5 mg/mL in 2 g/L NaCl (pH 1.2, adjusted by 1 N HCl) at 37°C. The suspension was first ultrasonicated for 5 min at 37°C and was adjusted to pH 6.8 with 1 N NaOH. Another 5 min ultrasonication at 37°C was conducted, and then the suspension was centrifuged for 10 min. Finally, the supernatant was filtered through an 0.22 μm filter, and the filtrate was further diluted to 500 μg/mL with Hank’s buffered saline solution (HBSS; Sigma-Aldrich, USA).

2.4. Functional Assay of hOAT1

Transfection of hOAT1 expressing stable line in MDCK II cells was established in Dr. Pritchard’s laboratory. Apical expression of hOAT1 and low uptake background of organic anions permit cells growing on a solid well plate to screen substances that are involved in hOAT1-mediated transport [39, 40]. The procedures of the PAH uptake study were followed by Zalups and Ahmad studies with minor modifications [41, 42]. First, 5 × 105 MDCK/hOAT1 cells were seeded in 24-well plates with a total volume of 2 mL, and medium were changed at the first 24 hr. After culturing for 48 hr, each well was preincubated with 1 mL of 37°C HBSS supplemented 10 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES, pH 7.4) for three consecutive 5 min periods. The buffer was then aspirated, and 350 μL of the aforementioned HBSS containing 5 μM [3H]-PAH (PerkinElmer, USA) were added to each well in the presence or absence of 200 μM probenecid. Uptake period of [3H]-PAH was 1 hr in a 37°C incubator. The reaction was quenched by rinsing each well with 1 mL of the “stopping buffer” which was composed of ice cold HBSS containing 10 mM HEPES (pH 7.4). To determine the cellular uptake of [3H]-PAH, 1 mL of 1 N NaOH was added into each well to lyze the cells. The plate was shaken with an orbital shaker overnight (at least 12 h). Subsequently, 700 μL of cell lysate was transferred into a counting vial and neutralized with an equal volume of 1 N HCl. The cell lysate was followed by adding 15 mL of Opti-Fluor (PerkinElmer, USA). The radioactivity was measured with a liquid scintillation counter (2100TR Tricarb, Packard, USA). Total protein of each well was determined by the Bradford method according to the instructions of the protein assay kit (BioRad, USA).

2.5. Functional Modulation Effects of CHM on hOAT1

A typical OAT1 substrate, [3H]-PAH, was administered to MDCK/hOAT1 cells in the presence or absence of CHM extracts. Frequently used 30 CHM formulae and 33 CHM single herbs were selected for the in vitro study. The [3H]-PAH uptake velocity differences between control ([3H]-PAH treated only) and CHM groups were measured to evaluate if CHM extracts would modulate hOAT1-mediated [3H]-PAH uptake. First, 5 × 105 MDCK/hOAT1 cells cultured in 24-well plate were conditioned as described above. Second, 350 μL of the aforementioned HBSS containing 50 μg/mL CHM extract and 2 μM [3H]-PAH were added to each well for 1 min exposure at 37°C. At the end of the exposure, each well was rinsed with a 1 mL stopping buffer. The subsequent procedures for the determination of intracellular [3H]-PAH and total protein were all the same with PAH uptake experiment as described above.

2.6. Cytotoxicity of CHM on MDCK and MDCK/hOAT1 Cells

Control MDCK II and MDCK/hOAT1 cells were seeded in a 96-well plate with a density of 5 × 104 cells per well. Cells were cultured for 48 hr with medium refreshment at the first 24 hr. Before treating the cells with CHM extracts, each well was washed twice with 37°C HBSS. Two hundred μL of CHM extract at different concentrations (5, 50 and 500 μg/mL) were added to each well and incubated for 48 hr. After treating with CHM extracts, each well was washed once with 37°C HBSS. Then 100 μL of 0.5 mg/mL thiazolyl blue tetrazolium bromide (MTT) were added to each well and incubated for 1 h. Finally, cells were lyzed with 100 μL DMSO for 15 min, and the absorbance was measured at 570 nm by a ELISA reader (Witec AG, German).

2.7. Animals

The animal study was approved by the Institutional Animal Care and Use Committee of the National Defense Medical Center (Taipei, Taiwan). Male Wistar rats weighing 350–400 g (8–10 weeks old) were used in the study. All the animals were housed in a standard animal maintenance facility for at least 1 week with free access to food and water before the experiment. Each CHM was prepared with 10 mL milli-Q water by weighing the recommended dose/weight of human × weight of the rat. Oral gavage of the effective CHM formulations in deionized water (from 10.5–70 mg, please refer to Supplementary 1, available online at doi: 10.1155/2012/967182) was conducted for 7 days. The reason for directly gavaging herbal formulations to animals is to present the study under the real physiological condition, in which the herbal medicine was absorbed in the living organisms. Rats in the control group were given deionized water. Rats in the study groups were given 1 mL CHM formulation and the syringe was washed with another 1 mL milli-Q water to ensure all the formulation was administered. Anesthesia was performed on the eighth day by intraperitoneal (ip) injection of pentobarbital sodium (50 mg/kg). Animals were placed on a thermo-regulated heating blanket throughout the study to maintain body temperature. PE-50 catheters were rinsed with normal saline (NS) and 50 IU heparin in NS for femoral vein and femoral artery cannulation, respectively. After cannulating of both the femoral vein and femoral artery, a priming dose of PAH/inulin (30 mg/kg) in NS was injected through the venous catheter; immediately, a continuous intravenous infusion of PAH/inulin (12 mg/mL) was given at a rate of 1 mL/100 g body weight to reach steady-state by an infusion pump (Harvard Apparatus, USA). Blood samples were taken from femoral artery at predose, 30, 45, and 60 min postdose. Plasma was obtained from centrifugation of blood samples at 13,000 rpm for 10 min. After blood sample collection, the animals were sacrificed with potassium chloride and left kidneys being excised and immediately stored in liquid nitrogen. Concentrations of PAH and inulin in plasma samples were then determined by liquid chromatography tandem mass spectrometry (LC-MS/MS).

2.8. Sample Analysis and Estimation of Rat Renal Hemodynamic

The analysis of PAH and inulin in rat plasma by LC-MS/MS was developed and verified in our laboratory [43]. The steady-state model was proposed without collection of urine samples [44]. The clearance (CLx) can be determined by the following equation: CLx = Ix   ×  IY/PL, where I 𝑋 was the concentration of the drugs (PAH and inulin) in the infusion solution, IY was the infusion rate, and PL was the concentration of the drugs in plasma [45]. Since both inulin and PAH are eliminated by the kidney without reabsorption, the effect of reabsorption on renal hemodynamic can be neglected [4648]. Clearance of PAH net secretion ( C L s e c P A H ), the most important parameter of renal hemodynamic that related to OAT1 in this study, can be estimated by the following equation: C L s e c P A H = CLPAHCLIn.

2.9. mRNA Isolation and cDNA Synthesis

Total RNA was isolated with Trizol Reagent (Invitrogen, USA) from pulverized rat renal tissue according to the manufacturer’s instruction. Total RNA extract was suspended in DEPC-treated water. RNA concentration and purity were estimated by measuring the optical density 260/280 nm. The quality and integrity of RNA was analyzed by agarose gel electrophoresis and the samples were stored at −80°C until used. To avoid genomic DNA contamination, each sample was treated with DNase I (Invitrogen, USA) according to the instruction manual.

First-strand cDNA was synthesized using a SuperScript First-Strand Synthesis Kit (Invitrogen, USA) according to the manufacturer’s instructions. Reverse transcription (RT) was performed at 42°C for 50 min containing 0.2 μg of RNA, 0.5 μg of oligo (dT)12–18, and 50 U of superScript II RNase H- RT. Subsequently, RT was inactivated by incubation at 70°C for 15 min, followed by treatment with Rnase H at 37°C for 20 min. cDNA was stored at −20°C before PCR.

2.10. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)

PCR was carried out using a DNA Engine Peltier Thermal Cycle (BioRad, Foster City, CA, USA). PCR amplification was performed in 33 cycles and the reaction conditions used were initial denaturation for 2 min at 94°C, denaturation for 15 s at 94°C, annealing for 30 s at 57°C, and elongation for 1 min at 68°C. For rOAT1 the primers were 5′-TGGCATAATACCGAAGAGCC-3′ (forward) and 3′-TGCTGCTGTTGATTCTGCTT-3′ (reverse), resulting in a 340-bp product. For GAPDH, the primers were 5′-CGGCAACTTCAACGGCACAGTCA-3′ (forward) and 3′-GGTTTCTCCAGGCGGCATGTCA-5′ (reverse), resulting in a 560-bp product. GAPDH was used as a control for variations in the input of RNA. Relative quantity was calculated by the ratio of the gene-specific and the appropriate GAPDH expression. RT-PCR products were resolved by electrophoresis in 1% agarose gel stained with ethidium bromide and visualized under ultraviolet light. The RT-PCR products generated with primers for rOAT1 were tested by sequencing (MB Mission Biotech, Taiwan) and were found to represent the predicted parts of the respective mRNAs.

2.11. Statistical Analysis

The statistical analysis was performed by one-way analysis of variance (ANOVA). Values are expressed as mean ± standard error (SE). P values less than 0.05 were considered significant. All analyses were performed using the Statistical Package Social Sciences software (SPSS 12, 2003, SPSS Inc, USA).

3. Results

3.1. Uptake of PAH

The uptake velocity of [3H]-PAH in MDCK/hOAT1 and control MDCK II cells in the presence or absence of OAT1 inhibitor, probenecid, was evaluated. For MDCK/hOAT1 cells, the rate was 9 . 9 4 ± 0 . 7 9  pmol/mg protein/min for treating with [3H]-PAH only, whereas the addition of probenecid dramatically diminished the rate to 0.54 ± 0.01 pmol/mg protein/min. On the other hand, control MDCK II cells only showed a rate of 0 . 1 0 ± 0 . 0 1  pmol/mg protein/min, which was almost the same even in the presence of probenecid. The results of both control MDCK II cells and MDCK/hOAT1 cells were similar to Zalups and Ahmad studies [41, 42], proving the function of hOAT1 in the plasma membranes and the repeatability of the experiment in our laboratory.

To determine a suitable uptake period of [3H]-PAH in the following CHM screening experiments, a time-dependent kinetic of [3H]-PAH uptake in MDCK/hOAT1 was conducted. The result showed that the uptake velocity of [3H]-PAH maintained linear before 1 min (Figure 1). Therefore, the uptake velocity of [3H]-PAH at 1 min in MDCK/hOAT1 is defined as the initial uptake rate. In the experiments of hOAT1 functional modulation by CHM, [3H]-PAH and CHM extract mixture was administered to MDCK/hOAT1 cells and was exposed for 1 min.

An overshoot of [3H]-PAH uptake in MDCK/hOAT1 cells is observed. The phenomenon was also reported and explained by Lu et al. [24] and Ueo et al. [49], who used hOAT1 transfected HeLa cells and HEK cells, respectively. The overshoot phenomenon is consistent with exchange-mediated secondary active transport in which an outwardly directed gradient for a cytosolic exchange partner (likely α-ketoglutarate) is depleted during the uptake experiment because of an abundance of the external exchange partner.

3.2. CHM In Vitro Screening

To evaluate the possibility of OAT1-mediated herb-drug interactions in vitro, the extracts of frequently used 30 CHM formulae and 33 single herbs had been tested to estimate whether clinical used CHM formulations would influence hOAT1-mediated [3H]-PAH uptake. The results of CHM formulae and CHM single herbs were summarized in Tables 1 and 2, respectively. Interestingly, almost all the tested CHM formulae had significant inhibition on hOAT1 function, while no enhancement of hOAT1 function was observed. Seven of the CHM formulae—Gui Zhi Fu Ling Wan (GZ), Liu Wei Ti Huang Wan (LW), Chia Wei Hsiao Yao San (CW), Chi Chu Ti Huan Wan (CC), Chih Po Ti Huang Wan (CP), Hsin I Ching Fei Tang (HI), and Lung Tan Hsieh Kan Tang (LT)—showed over 50% significant inhibition of hOAT1 uptake ability. In CHM single herbs, half showed significant inhibition on hOAT1 function, but most were about 20–30% inhibition. Only Huang Qin (HQ) had about 50% functional inhibition on hOAT1. Also, two of the CHM single herbs—Jie Geng and Gan Cao—were found to slightly enhance hOAT1-mediated [3H]-PAH uptake. Furthermore, seven CHM formulae and two CHM single herbs of the most effective hOAT1 inhibitors showed concentration-dependent manner on hOAT1 functional inhibition (Figure 2). Overall, it seems that CHM single herbs are not so effective on the functional inhibition of hOAT1as CHM formulae are.


Inhibition orderChinese herbal medicine[3H]-PAH uptake (% of control)aSignificanceb

1Gui Zhi Fu Ling Wan25.89 ± 0.85 ***
2Liu Wei Ti Huang Wan32.62 ± 0.74 ***
3Chia Wei Hsiao Yao San43.00 ± 1.53 ***
4Chi Chu Ti Huang Wan43.13 ± 2.40 ***
5Chih Po Ti Huang Wan44.55 ± 3.21 ***
6Hsin I Ching Fei Tang45.41 ± 1.19 ***
7Lung Tan Hsieh Kan Tang47.58 ± 3.85 ***
8Kan Lu Yin51.02 ± 0.64 ***
9Hsiao Chai Hu Tang56.44 ± 3.27 ***
10Pan Hsia Hsieh Hsin Tang57.99 ± 3.45 ***
11Tan Kuei Shao Yao Tang62.22 ± 1.68 ***
12Chuan Chiung Cha Tiao San63.25 ± 0.80 ***
13Hsieh Fu Chu Yu Tang65.15 ± 1.62 ***
14Chang Er San68.95 ± 5.02 ***
15Xin Yi San69.40 ± 3.00 ***
16Shao Yao Gan Cao Tang72.27 ± 4.18 ***
17Yin Qiao San75.24 ± 2.83 ***
18Shu Ching Huo Hsieh Tang77.39 ± 3.85 ***
19Ten Wang Pu Hsin Tan77.56 ± 1.06 ***
20Hsiao Ching Lung Tang79.29 ± 1.84 ***
21Tu Huo Chi Sheng Tang80.84 ± 3.92 ***
22Ping Wei San82.47 ± 2.76 ***
23Pu Chung I Chi Tang83.43 ± 3.12 ***
24Ko Ken Tang89.72 ± 1.43 *
25Ma Hsing Kan Shih Tang90.77 ± 3.83 *
26Mai Men Dong Tang93.15 ± 1.80
27San Ju Yin93.75 ± 4.83
28Hsiang Sha Liu Chun Tzu Tang96.96 ± 7.02
29Kuei Pi Tang97.74 ± 5.91
30Huo Hsiang Cheng Chi San102.63 ± 3.42 

aResults are expressed as mean ± SE (n = 3).
bStatistic is performed by one-way ANOVA with posthoc LSD. *P < 0.05, ***P < 0.001.

Inhibition orderChinese herbal medicine[3H]-PAH uptakea (% of control)Significanceb

1Huang Qin 50.76 ± 0.42 ***
2Huang Lien 62.71 ± 2.93 ***
3Chen Pi 73.43 ± 3.08 ***
4Bai Shouh 74.59 ± 1.22 ***
5Hwang Bs 75.46 ± 3.60 ***
6Huang Qi 77.50 ± 1.07 ***
7Ge Gen 77.52 ± 1.87 ***
8Suan Zao Ren 79.21 ± 2.05 ***
9Sha Ren 79.28 ± 5.33 ***
10Du Zhong 79.90 ± 9.46 ***
11Shiang Fu Zhi 82.50 ± 2.24 **
12Ren San 83.73 ± 5.30 **
13Sheng Di Huang 84.60 ± 6.44 *
14Fu Ling 85.77 ± 1.49 *
15Tan San 86.17 ± 6.47 *
16Yi Yi Ren 87.33 ± 1.06 *
17Chuan Kung 90.13 ± 6.57
18Jin Yin Hua 90.41 ± 3.10
19Ban Shia 90.60 ± 2.01
20Tian Lou Gen 91.09 ± 5.99
21San Yao 91.64 ± 1.99
22Mai Men Tung 91.89 ± 7.06
23Zhi Ke 92.93 ± 0.75
24Yan Hu Nan 94.23 ± 2.69
25Niu Shi 98.55 ± 4.03
26Tang Kuei 98.13 ± 3.17
27Bai Zhu100.48 ± 4.89
28Bai Zhi101.99 ± 2.69
29Shing Ren104.68 ± 3.94
30Chai Hu105.87 ± 5.45
31Fang Feng107.05 ± 4.65
32Jie Geng111.14 ± 5.33 *
33Gan Cao115.99 ± 1.42 **

aResults were expressed as mean ± SE (n = 3).
bStatistics: one-way ANOVA, LSD post-hoc; significantly different from control.
(*P < 0.05, **P < 0.05, ***P < 0.001).
3.3. Cytotoxicity of CHM Extracts on MDCK/hOAT1 and Control MDCK II Cells

To evaluate whether the selected CHM have potential hOAT1-induced nephrotoxicity, various concentrations (5, 50 and 500 μg/mL) of CHM extracts were incubated with MDCK/hOAT1 and control MDCK II cells, and cytotoxicities of CHM extracts on the two types of cells were then evaluated. The result showed that CHM formulae were innoxious to MDCK/hOAT1 cells, while it seemed that CHM formulae were harmful to control MDCK II cells. Comparing to MDCK/hOAT1 cells, LW at 500 μg/mL and CW showed significant reduction of cell viability in control MDCK II cells (Figure 3). Similar results were observed in CHM single herbs at 5 and 50 μg/mL; the cell viabilities of MDCK/hOAT1 cells were higher than control MDCK II cells when administrating the cells with Huang Qin (HQ) and Huang Lien (HL). However, HQ and HL at high concentration (500 μg/mL) presented totally opposite outcomes between MDCK/hOAT1 and control MDCK II cells. In HQ experiment, control MDCK II cells maintained about 80% cell viability when treating cells with high concentration of HQ; on the contrary, MDCK/hOAT1 cells showed dramatica reduction of cell viability in the presence of the same concentration of HQ. A similar phenomenon was observed in an HL high-concentration experiment, whereas it was control MDCK II cells which were killed by HL but not MDCK/hOAT1 cells (Figure 3). Cytotoxicity of HQ in MDCK/hOAT1 cells could be reversed by 100 μM of probenecid; nevertheless, that of HL in control MDCK II cells was irreversible by the same treatment of probenecid (Figure 4).

3.4. Effects of CHM on Rat Renal Hemodynamic

To examine whether the in vitro hOAT1 inhibitors also influence renal secretion in vivo, positive control (cisplatin, ip 5 mg/kg) and effective hOAT1 inhibitors (GZ, LW, CW, CC, CP, HI, LT, HQ, and HL) were administered to Wistar rats for 7 days, and parameters of renal hemodynamic were evaluated. The results were summarized in Table 3. Compared to control group, rats injected with cisplatin exhibited significant reductions in CLPAH, CLIn, and C L s e c P A H . On the other hand, CLPAH of GZ and CW were found to have significantly diminished, which could have been caused by the reduction in C L s e c P A H . Also, HI and LT showed significant reduction in CLIn, while CLPAH of both HI and LT were not affected. LW, CP, and HQ were found to enhance C L s e c P A H ; however, they did not show statistical significance. In the experiment of GZ high dose (HD), dose-dependent manners were observed in CLPAH and C L s e c P A H , indicating that elevated dose of CHM should modulate the ability of tubular secretion rather than glomerular filtration.


Treatment C L P A H a , b , d C L I n a , b , d C L S e c P A H a , b , d

Control3.32 ± 0.070.99 ± 0.032.34 ± 0.05
Cisplatin 2.04 ± 0.31*** 0.64 ± 0.08*** 1.40 ± 0.24***
Gui Zhi Fu Ling Wan 2.86 ± 0.21*0.97 ± 0.06 1.89 ± 0.16*
Liu Wei Di Huang Wan3.57 ± 0.141.05 ± 0.03 2.52 ± 0.14
Chia Wei Hsiao Yao San 2.88 ± 0.10*0.92 ± 0.03 1.96 ± 0.09*
Chi Chu Di Huang Wan3.16 ± 0.02 0.88 ± 0.04* 2.28 ± 0.02
Chih Po Di Huang Wan3.43 ± 0.060.89 ± 0.03 2.54 ± 0.04
Hsin I Ching Fei Tang3.28 ± 0.10 0.80 ± 0.03*** 2.48 ± 0.08
Lung Tan Hsieh Kan Tang3.14 ± 0.12 0.83 ± 0.04** 2.31 ± 0.13
Gui Zhi Fu Ling Wan HDc 2.70 ± 0.11**0.92 ± 0.03 1.79 ± 0.10**
Huang Qin3.50 ± 0.180.98 ± 0.03 2.52 ± 0.16
Huang Lien3.27 ± 0.181.00 ± 0.04 2.28 ± 0.15

aCLPAH = CLIn + CLSec PAH.
bResults were expressed as mean ± SE (mL/min/100 g BW) (n = 5–7).
cHD: high dose.
dStatistics: one-way ANOVA, LSD post-hoc; significantly different from control (*P < 0.05, **P < 0.005, ***P < 0.001).
3.5. Regulations of rOAT1 mRNA Expression by CHM

To obtain direct evidence regarding the role of OAT1 in the renal function inhibited by CHM, the expression of rOAT1 mRNA was evaluated. Kidneys from the control group, cisplatin, GZ, GZ HD, LW (negative control), and CW were excised, and rOAT1 mRNA was evaluated (Figure 5). Compared to control, cisplatin showed significant reduction in rOAT1 mRNA expression. GZ and GZ HD were not only significant downregulation of rOAT1 mRNA expression, but also showed a dose-dependent manner. On the contrary, rOAT1 expression of LW and CW remained steady.

4. Discussion

The roles of OAT1 in physiology [5052], drug induced nephrotoxicity [34, 35, 53, 54], and drug-drug interactions have been studied intensively. However, most of these studies focus on the relationships between OAT1 and synthesized drugs, whereas few focus on that between OAT1 and herbal medicines. The contribution of the presented study is that we are the first ones who evaluated the effects of a large amount of clinical prescribed CHM formulations on OAT1-mediated transport, via in vitro screening, in vivo hemodynamic monitoring, and OAT1 mRNA expression in rat kidney. The information from our results should be useful in estimating potential herb-drug interactions.

Phytochemicals were rarely addressed in the presented study because the combinations and interactions of phytochemicals in CHM formulations are too complex to be analyzed. For example, histidine and histamine in Fu Ling (Poriae cocos) show activation and inhibition on histamine receptor H1, respectively [7]. One single herb may contain several phytochemicals whereas one formula contains many other single herbs. Synergism and antagonism of phytochemicals within CHM single herbs, and that of CHM single herbs within CHM formulae, make it difficult to evaluate which one plays the major role in herb-drug interactions. Therefore, the strategy of this study is to evaluate CHM that is most commonly prescribed for patients and most ubiquitously used by everyone. The CHM formulations were all purchased from a good manufacturing practice (GMP) pharmaceutical manufacture which ruled out the bias caused by the diversity of the resource, quality, and generating process. Besides, these CHM formulations are extracted and processed by the manufacture to form granulated powder, so that patients can take these CHM formulations directly without further processing procedures. Namely, we are also able to extract these CHM formulations by simulating the condition of the gastrointestinal tract, for these CHM formulations undergo the same pathway in patients.

Before screening the functional modulation effects of CHM on hOAT1, the uptake velocity of [3H]-PAH was evaluated with exactly the same procedures as Zalups and Ahmad [41, 42] previously reported.

In the experiment of in vitro screening, 25 of 30 CHM formulae and 16 of 33 CHM single herbs were found to significantly inhibit hOAT1-mediated transport. We consider that so many CHM formulations showing their significance may be due to the small standard errors in each group. Therefore, we only selected GZ, LW, CW, CC, CP, HI, LT, HQ, HL (CHM formulae exhibited over 50% inhibition on hOAT1-mediated transport), and HQ, HL (two of the most effective CHM single herbs that inhibited hOAT1-mediated transport) into the following concentration-dependent and cytotoxicity experiments.

As Figure 2 shows, all the CHM formulations exhibited concentration-dependent manners, and IC50 was from 18.67 to 44.24 μg/mL except HL (339.26 μg/mL). On the other hand, an interesting pattern was observed to be a contrast with the recent hypothesis of OAT1 mediated nephrotoxicity; basolateral uptake of substrates from blood into renal proximal tubular cells by OAT1 causes intracellular accumulation of the substrates and further induces tubular damage [3335, 55]. Should these selected CHM formulations be cytotoxic via OAT1-mediated transport, cell viability of MDCK/hOAT1 cells would be much lower than that of control MDCK II cells. However, we observed a totally opposite phenomenon in the study. That is, cell viability of MDCK/hOAT1 cells was generally higher than control MDCK II cells (except HQ at 500 μg/mL). Also, CHM-formulations-induced cytotoxicity on control MDCK II cells were not concentration-dependent, indicating that there might be a nonspecific factor which injures control MDCK II cells. This implies that it was not associated with OAT1-mediated transport. It is very interesting that at high concentration (500 μg/mL), HQ and HL showed severe toxicity to MDCK/hOAT1 cells and control MDCK II cells, respectively. Cytotoxicity of HQ could be reversed by hOAT1 inhibitor, probenecid, whereas HL could not. Gao et al. [56] found that Scutellaria baicalensis (known as HQ) extract was cytotoxic to various lung cancer cells, and cytotoxicity of Scutellaria baicalensis might be due to the stoichiometric combination of its three active components, baicalin, baicalein, and wogonin. In this case, HQ extract at 500 μg/mL showed cytotoxic to control MDCK II cells but was much more aggravated in MDCK/hOAT1 cells; therefore, we assume that uptake of active components in HQ extract by hOAT1 may lead to toxic effect as the aforementioned hypothesis. On the other hand, it is hard to figure out why HL extract at 500 μg/mL induced severe cytotoxicity on control MDCK II cells while it was innoxious to MDCK/hOAT1 cells. Although we do not know the possible mechanisms of HL-induced cytotoxicity on control MDCK II cells, it is worth noting that HL at high level in body may cause OAT1-independent nephrotoxicity, since MDCK II cells are renal distal tubular epithelial cells, in which OAT1 did not express. Overall, the in vitro cytotoxicity experiment provides information that most CHM formulations tested in the study will not cause cytotoxicity via hOAT1-mediated transport, except HQ at 500 μg/mL. However, the results are incapable of indicating that these CHM formulations are nephrotoxicity-free, for only distal tubular cells were tested in this study. Indeed, it has been suggested that using different cell lines can model differential susceptibilities of corresponding cell types to injury in vivo [57, 58].

Intraperitoneal injection of cisplatin, a commonly used model drug that induces rat nephrotoxicity [5961], is served as positive control to ensure the feasibility of the whole animal experimental system and our new LC-MS/MS analytical method. The result was satisfied that significant reductions of whether CLPAH, CLIn, or C L s e c P A H were observed (Table 3). Cisplatin also inhibited the expression of rOAT1 in kidney (Figure 5), but the downregulation was not so effective as Dan et al. [62] and Morisaki et al. [63] reported. The reason may be that Dan et al. and Morisaki et al. used higher dose of cisplatin (10 mg/kg) than us (5 mg/kg) for injection. On the other hand, GZ was observed to significantly inhibit CLPAH, C L s e c P A H , and expression of rOAT1 mRNA, indicating that the reduction of renal function by GZ might be due to not only functional inhibition of OAT1 but also downregulation of OAT1 expression in the kidney. It is also possible that CHM preparations only modulate OAT1-mediated transport without regulating the expression of OAT1. In the case of CW, the in vitro data showed 57% inhibition on hOAT1-mediated transport (Table 1), the in vivo data showed significant reduction in CLPAH and C L s e c P A H (Table 3), whereas the expression of rOAT1 mRNA remained still in comparison to control group (Figure 5). There are also CHM preparations that present different results from in vitro and in vivo. For instance, LW, CP, HI, and HQ are the cases that were found to effectively inhibit hOAT1 in vitro whereas slightly, though nonstatistical significant, enhanced C L s e c P A H   in vivo. We also selected LW to perform the experiment of RT-PCR to test the existence of system error (the expression of rOAT1 mRNA is significantly down- or upregulated while C L s e c P A H remains steady) and found that the expression of rOAT1 mRNA was not significantly regulated as well as renal hemodynamic.

Renal active secretion involves transporters-mediated basolateral uptake and apical efflux. Hence, modulation on these transporters by CHM makes it complex to elucidate the mechanisms of herb-drug interactions in vivo. Previous studies have reported that renal excretion of PAH is associated with the expression of OAT1 rather than another important basolateral transporter, OAT3, functioning as well as OAT1 [64]. In this OAT1 focusing study, we chose PAH as an in vivo model substrate, meaning that we can neglect the effects of CHM on OAT3 in elucidating parameters of renal hemodynamic in vivo, yet it is insufficient to rule out the impact of apical efflux transporters. It has been reported that multidrug resistance protein 4 (MRP4) located at apical side is a novel PAH efflux transporter [65]. As a result, studying modulation of MRP4 by CHM should be worthwhile to clarify the mechanism of potential OAT1-mediated herb-drug interactions in kidney.

5. Conclusion

In conclusion, from in vitro to in vivo, we proceeded step by step to narrow down CHM formulations that might potentially induce OAT1-related herb-drug interactions. In such interactions, GZ and CW may reduce renal active secretion through inhibition of OAT1-mediated transport, expression of OAT1, or both. The methodologies of the study should be useful in evaluating modulation of drug transporter by CHM; the results of the study should be helpful in abounding information of CHM safety database.

Authors’ Contribution

C.-C. Lin and H.-Y. Fan contributed equally to this work.

Acknowledgments

This study was supported by a partial Grant no. 98–70 from Cheng Hsin General Hospital and a partial Grant no. 100-EC-17-A-20-S1-028 from Ministry of Economic Affairs. The authors are grateful to Dr. Hsan-Jan Yen for his expert technical assistnce in kidney RNA study.

Supplementary Materials

Summary of rat dose calculated from human dose: the suggesting dosage of CHM formulations for human (we assume a 60 kg adult) followed the instruction of the manufacture. The dosage used in rats (we assume a 350 mg rat) was directly measured by multiplying the daily dose of human by the ratio of rat to human body weight.

  1. Supplementary Material

References

  1. C. M. Corns, “Herbal remedies and clinical biochemistry,” Annals of Clinical Biochemistry, vol. 40, no. 5, pp. 489–507, 2003. View at: Publisher Site | Google Scholar
  2. P. A. G. M. De Smet, “Herbal medicine in Europe—relaxing regulatory standards,” The New England Journal of Medicine, vol. 352, no. 12, pp. 1176–1178, 2005. View at: Publisher Site | Google Scholar
  3. B. C. Foster, J. T. Arnason, and C. J. Briggs, “Natural health products and drug disposition,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 203–226, 2005. View at: Publisher Site | Google Scholar
  4. C. Holtz, Global Health Care: Issues and Policies, Jones and Bartlett, Sudbury, Mass, USA, 2007.
  5. M. M. Robinson and X. Zhang, World Medicines Situation 2011, Traditional Medicines: Global Situation, Issues and Challenges, WHO, 2011.
  6. Y. P. Zhu and H. J. Woerdenbag, “Traditional Chinese herbal medicine,” Pharmacy World and Science, vol. 17, no. 4, pp. 103–112, 1995. View at: Publisher Site | Google Scholar
  7. E. Chan, M. Tan, J. Xin, S. Sudarsanam, and D. E. Johnson, “Interactions between traditional Chinese medicines and Western therapeutics,” Current Opinion in Drug Discovery and Development, vol. 13, no. 1, pp. 50–65, 2010. View at: Google Scholar
  8. F. P. Chen, T. J. Chen, Y. Y. Kung et al., “Use frequency of traditional Chinese medicine in Taiwan,” BMC Health Services Research, vol. 7, article 26, 2007. View at: Publisher Site | Google Scholar
  9. M. Jiang, J. Yang, C. Zhang et al., “Clinical studies with traditional Chinese medicine in the past decade and future research and development,” Planta Medica, vol. 76, no. 17, pp. 2048–2064, 2010. View at: Publisher Site | Google Scholar
  10. J. Singhuber, M. Zhu, S. Prinz, and B. Kopp, “Aconitum in Traditional Chinese Medicine-A valuable drug or an unpredictable risk?” Journal of Ethnopharmacology, vol. 126, no. 1, pp. 18–30, 2009. View at: Publisher Site | Google Scholar
  11. Y. Motoo, I. Arai, I. Hyodo, and K. Tsutani, “Current status of Kampo (Japanese herbal) medicines in Japanese clinical practice guidelines,” Complementary Therapies in Medicine, vol. 17, no. 3, pp. 147–154, 2009. View at: Publisher Site | Google Scholar
  12. P. D. L. Chao, S. P. Lin, P. P. Wu et al., “Different influences on tacrolimus pharmacokinetics by coadministrations of Zhi Ke and Zhi Shi in rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 751671, 6 pages, 2011. View at: Publisher Site | Google Scholar
  13. S. F. Zhou, “Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition,” Xenobiotica, vol. 38, no. 7-8, pp. 802–832, 2008. View at: Publisher Site | Google Scholar
  14. A. Grover and L. Z. Benet, “Effects of drug transporters on volume of distribution,” AAPS Journal, vol. 11, no. 2, pp. 250–261, 2009. View at: Publisher Site | Google Scholar
  15. R. H. Ho and R. B. Kim, “Transporters and drug therapy: implications for drug disposition and disease,” Clinical Pharmacology and Therapeutics, vol. 78, no. 3, pp. 260–277, 2005. View at: Publisher Site | Google Scholar
  16. R. B. Kim, “Transporters and drug discovery: why, when, and how,” Molecular Pharmaceutics, vol. 3, no. 1, pp. 26–32, 2006. View at: Publisher Site | Google Scholar
  17. C. J. Endres, P. Hsiao, F. S. Chung, and J. D. Unadkat, “The role of transporters in drug interactions,” European Journal of Pharmaceutical Sciences, vol. 27, no. 5, pp. 501–517, 2006. View at: Publisher Site | Google Scholar
  18. A. A. K. El-Sheikh, R. Masereeuw, and F. G. M. Russel, “Mechanisms of renal anionic drug transport,” European Journal of Pharmacology, vol. 585, no. 2-3, pp. 245–255, 2008. View at: Publisher Site | Google Scholar
  19. W. Lee and R. B. Kim, “Transporters and renal drug elimination,” Annual Review of Pharmacology and Toxicology, vol. 44, pp. 137–166, 2004. View at: Publisher Site | Google Scholar
  20. H. Miyazaki, T. Sekine, and H. Endou, “The multispecific organic anion transporter family: properties and pharmacological significance,” Trends in Pharmacological Sciences, vol. 25, no. 12, pp. 654–662, 2004. View at: Publisher Site | Google Scholar
  21. T. Sekine, N. Watanabe, M. Hosoyamada, Y. Kanai, and H. Endou, “Expression cloning and characterization of a novel multispecific organic anion transporter,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18526–18529, 1997. View at: Publisher Site | Google Scholar
  22. D. H. Sweet, N. A. Wolff, and J. B. Pritchard, “Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney,” The Journal of Biological Chemistry, vol. 272, no. 48, pp. 30088–30095, 1997. View at: Publisher Site | Google Scholar
  23. N. A. Wolff, A. Werner, S. Burkhardt, and G. Burckhardt, “Expression cloning and characterization of a renal organic anion transporter from winter flounder,” FEBS Letters, vol. 417, no. 3, pp. 287–291, 1997. View at: Publisher Site | Google Scholar
  24. R. Lu, B. S. Chan, and V. L. Schuster, “Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C,” American Journal of Physiology, vol. 276, no. 2, pp. F295–F303, 1999. View at: Google Scholar
  25. N. Anzai, Y. Kanai, and H. Endou, “Organic anion transporter family: current knowledge,” Journal of Pharmacological Sciences, vol. 100, no. 5, pp. 411–426, 2006. View at: Publisher Site | Google Scholar
  26. W. H. Dantzler, “Renal organic anion transport: a comparative and cellular perspective,” Biochimica et Biophysica Acta, vol. 1566, no. 1-2, pp. 169–181, 2002. View at: Publisher Site | Google Scholar
  27. A. Somogyi, “Renal transport of drugs: specificity and molecular mechanisms,” Clinical and Experimental Pharmacology and Physiology, vol. 23, no. 10-11, pp. 986–989, 1996. View at: Google Scholar
  28. T. Sekine, S. H. Cha, and H. Endou, “The multispecific organic anion transporter (OAT) family,” Pflugers Archiv European Journal of Physiology, vol. 440, no. 3, pp. 337–350, 2000. View at: Google Scholar
  29. D. H. Sweet, “Organic anion transporter (Slc22a) family members as mediators of toxicity,” Toxicology and Applied Pharmacology, vol. 204, no. 3, pp. 198–215, 2005. View at: Publisher Site | Google Scholar
  30. A. N. Rizwan and G. Burckhardt, “Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles,” Pharmaceutical Research, vol. 24, no. 3, pp. 450–470, 2007. View at: Publisher Site | Google Scholar
  31. Y. Uwai, R. Taniguchi, H. Motohashi, H. Saito, M. Okuda, and K. I. Inui, “Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3,” Drug Metabolism and Pharmacokinetics, vol. 19, no. 5, pp. 369–374, 2004. View at: Google Scholar
  32. G. Burckhardt and B. C. Burckhardt, “In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy,” Handbook of Experimental Pharmacology, vol. 201, pp. 29–104, 2011. View at: Publisher Site | Google Scholar
  33. A. S. Mulato, E. S. Ho, and T. Cihlar, “Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 10–15, 2000. View at: Google Scholar
  34. E. S. Ho, D. C. Lin, D. B. Mendel, and T. Cihlar, “Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 383–393, 2000. View at: Google Scholar
  35. T. Cihlar, D. C. Lin, J. B. Pritchard, M. D. Fuller, D. B. Mendel, and D. H. Sweet, “The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1,” Molecular Pharmacology, vol. 56, no. 3, pp. 570–580, 1999. View at: Google Scholar
  36. S. Wada, M. Tsuda, T. Sekine et al., “Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs,” Journal of Pharmacology and Experimental Therapeutics, vol. 294, no. 3, pp. 844–849, 2000. View at: Google Scholar
  37. P. C. O. T. P. S. R. O. China, Pharmacopoeia of the People's Republic of Chinaed, Chinese Medical Science Press, Beijin, China, 1st edition, 2010.
  38. S. C. Hsieh, J. N. Lai, C. F. Lee, F. C. Hu, W. L. Tseng, and J. D. Wang, “The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 6, pp. 609–619, 2008. View at: Publisher Site | Google Scholar
  39. A. G. Aslamkhan, Y. H. Han, X. P. Yang, R. K. Zalups, and J. B. Pritchard, “Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in madin-darby canine kidney cells,” Molecular Pharmacology, vol. 63, no. 3, pp. 590–596, 2003. View at: Publisher Site | Google Scholar
  40. A. Aslamkhan, Y. H. Han, R. Walden, D. H. Sweet, and J. B. Pritchard, “Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells,” American Journal of Physiology, vol. 285, no. 4, pp. F775–F783, 2003. View at: Google Scholar
  41. R. K. Zalups and S. Ahmad, “Handling of cysteine S-conjugates of methylmercury in MDCK cells expressing human OAT1,” Kidney International, vol. 68, no. 4, pp. 1684–1699, 2005. View at: Publisher Site | Google Scholar
  42. R. K. Zalups and S. Ahmad, “Handling of the homocysteine S-conjugate of methylmercury by renal epithelial cells: role of organic anion transporter 1 and amino acid transporters,” Journal of Pharmacology and Experimental Therapeutics, vol. 315, no. 2, pp. 896–904, 2005. View at: Publisher Site | Google Scholar
  43. C. C. Lin, C. W. Kuo, and L. H. Pao, “Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of p-aminohippuric acid and inulin in rat plasma for renal function study,” Analytical and Bioanalytical Chemistry, vol. 398, no. 2, pp. 857–865, 2010. View at: Publisher Site | Google Scholar
  44. E. Schnurr, W. Lahme, and H. Kuppers, “Measurement of renal clearance of inulin and PAH in the steady state without urine collection,” Clinical Nephrology, vol. 13, no. 1, pp. 26–29, 1980. View at: Google Scholar
  45. P. A. Fischer, C. B. Bogoliuk, A. J. Ramirez, R. A. Sanchez, and L. D. Masnatta, “A new procedure for evaluation of renal function without urine collection in rat,” Kidney International, vol. 58, no. 3, pp. 1336–1341, 2000. View at: Publisher Site | Google Scholar
  46. R. Marsilio, M. Naturale, P. Manghi et al., “Rapid and simple determination of inulin in biological fluids by high-performance liquid chromatography with light-scattering detection,” Journal of Chromatography B, vol. 744, no. 2, pp. 241–247, 2000. View at: Publisher Site | Google Scholar
  47. R. H. K. Mak, J. A. Dahhan, and D. Azzopardi, “Measurement of glomerular filtration rate in children after renal transplantation,” Kidney International, vol. 23, no. 2, pp. 410–413, 1983. View at: Google Scholar
  48. A. Pastore, S. Bernardini, L. Dello Strologo, G. Rizzoni, C. Cortese, and G. Federici, “Simultaneous determination of inulin and p-aminohippuric acid in plasma and urine by reversed-phase high-performance liquid chromatography,” Journal of Chromatography B, vol. 751, no. 1, pp. 187–191, 2001. View at: Publisher Site | Google Scholar
  49. H. Ueo, H. Motohashi, T. Katsura, and K. I. Inui, “Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1,” Biochemical Pharmacology, vol. 70, no. 7, pp. 1104–1113, 2005. View at: Publisher Site | Google Scholar
  50. R. Schneider, C. Sauvant, B. Betz et al., “Downregulation of organic anion transporters OAT1 and OAT3 correlates with impaired secretion of para-aminohippurate after ischemic acute renal failure in rats,” American Journal of Physiology, vol. 292, no. 5, pp. F1599–F1605, 2007. View at: Publisher Site | Google Scholar
  51. A. Enomoto, M. Takeda, A. Tojo et al., “Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1711–1720, 2002. View at: Publisher Site | Google Scholar
  52. A. Enomoto and H. Endou, “Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease,” Clinical and Experimental Nephrology, vol. 9, no. 3, pp. 195–205, 2005. View at: Publisher Site | Google Scholar
  53. K. Y. Jung, M. Takeda, M. Shimoda et al., “Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1,” Life Sciences, vol. 70, no. 16, pp. 1861–1874, 2002. View at: Publisher Site | Google Scholar
  54. M. Takeda, E. Babu, S. Narikawa, and H. Endou, “Interaction of human organic anion transporters with various cephalosporin antibiotics,” European Journal of Pharmacology, vol. 438, no. 3, pp. 137–142, 2002. View at: Publisher Site | Google Scholar
  55. M. Tsuda, T. Sekine, M. Takeda et al., “Transport of ochratoxin a by renal multispecific organic anion transporter 1,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 3, pp. 1301–1305, 1999. View at: Google Scholar
  56. J. Gao, W. A. Morgan, A. Sanchez-Medina, and O. Corcoran, “The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells,” Toxicology and Applied Pharmacology, vol. 254, no. 3, pp. 221–228, 2011. View at: Publisher Site | Google Scholar
  57. R. T. Bonham, M. R. Fine, F. M. Pollock, and E. A. Shelden, “Hsp27, Hsp70, and metallothionein in MDCK and LLC-PK1 renal epithelial cells: effects of prolonged exposure to cadmium,” Toxicology and Applied Pharmacology, vol. 191, no. 1, pp. 63–73, 2003. View at: Publisher Site | Google Scholar
  58. L. B. Zimmerhackl, F. Momm, G. Wiegele, and M. Brandis, “Cadmium is more toxic to LLC-PK1 cells than to MDCK cells acting on the cadherin-catenin complex,” American Journal of Physiology, vol. 275, no. 1, pp. F143–F153, 1998. View at: Google Scholar
  59. A. Kuhad, N. Tirkey, S. Pilkhwal, and K. Chopra, “Renoprotective effect of Spirulina fusiformis on cisplatin-induced oxidative stress and renal dysfunction in rats,” Renal Failure, vol. 28, no. 3, pp. 247–254, 2006. View at: Publisher Site | Google Scholar
  60. K. W. Lee, J. Y. Jeong, B. J. Lim et al., “Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity,” Toxicology, vol. 257, no. 3, pp. 137–143, 2009. View at: Publisher Site | Google Scholar
  61. T. Tsuji, A. Kato, H. Yasuda et al., “The dimethylthiourea-induced attenuation of cisplatin nephrotoxicity is associated with the augmented induction of heat shock proteins,” Toxicology and Applied Pharmacology, vol. 234, no. 2, pp. 202–208, 2009. View at: Publisher Site | Google Scholar
  62. H. Dan, R. X. Peng, Y. Ao, and Y. H. Liu, “Segment-specific proximal tubule injury in tripterygium glycosides intoxicated rats,” Journal of Biochemical and Molecular Toxicology, vol. 22, no. 6, pp. 422–428, 2008. View at: Publisher Site | Google Scholar
  63. T. Morisaki, T. Matsuzaki, K. Yokoo et al., “Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats,” Pharmaceutical Research, vol. 25, no. 11, pp. 2526–2533, 2008. View at: Publisher Site | Google Scholar
  64. A. Brandoni, N. Anzai, Y. Kanai, H. Endou, and A. M. Torres, “Renal elimination of p-aminohippurate (PAH) in response to three days of biliary obstruction in the rat. The role of OAT1 and OAT3,” Biochimica et Biophysica Acta, vol. 1762, no. 7, pp. 673–682, 2006. View at: Publisher Site | Google Scholar
  65. P. H. E. Smeets, R. A. M. H. Van Aubel, A. C. Wouterse, J. J. M. W. Van Den Heuvel, and F. G. M. Russel, “Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter,” Journal of the American Society of Nephrology, vol. 15, no. 11, pp. 2828–2835, 2004. View at: Publisher Site | Google Scholar

Copyright © 2012 Chang-Ching Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views1891
Downloads865
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.